FluroTest Provides System Development Update; Reports globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.
/PRNewswire/ - FluroTech LTD. (TSXV: TEST) (OTCQB: FLURF) and wholly owned subsidiary FluroTest Diagnostic Systems ("FluroTest" or The Company), a diagnostics.
/PRNewswire/ - FluroTech LTD. (TSXV: TEST) (OTCQB: FLURF) and wholly owned subsidiary FluroTest Diagnostics Systems ("FluroTest" or The Company), a diagnostics.
CALGARY, AB, May 10, 2021 /PRNewswire/ -
FluroTech Ltd. (TSXV: TEST) (OTCQB: FLURF) and wholly owned subsidiary FluroTest or The Company), a diagnostics technology leader in high output rapid antigen testing for the detection of SARS-CoV-2 and other pathogens, today announces the next phase of its ongoing clinical trials with its trial partner Toolbox Medical Innovations ( Toolbox ).
The Company is pleased to report that approximately 600 volunteer participants, including both symptomatic and asymptomatic individuals, are being identified from six clinical site locations across California, Texas, Colorado, Rhode Island and Florida (with two sites) to determine performance detection results alongside a comparator RT-PCR assay. The data collected from this and the upcoming pilot program with California-based Total Testing Solutions (previously announced in the Company s news release dated May 3, 2021) will be used to support submissions for Emergency Use Authorization ( EUA
FluroTest or The Company), a first-mover in surge-scale rapid antigen testing for the detection of SARS-CoV-2 and other pathogens, are pleased to announce based on the data collected to date that the FluroTest platform will be capable of detecting the primary variants of concern now spreading across North America and fueling serious outbreaks around the world.
Many of the variants of concern are mutations that alter the viral structure through the spike ( S ) protein found on the molecular surface. FluroTest s antigen immunoassay detects the nucleocapsid ( N ) protein, which is found deep within the virus structure and, so far, remains relatively unaffected by major mutations in the main variants of concern. FluroTest works with the world s leading reagent suppliers of the antibody pairs that are used in the Pandemic Defense Platform Immunoassay. Additionally, they have confirmed that the antibody pairs FluroTest uses can detect the UK, South African and Brazilian variants and t